Regencell Bioscience Holdings Limited shares rise over 10% pre-market, currently trading at $26.41.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) shares rose over 10% in pre-market trading on March 13, 2026, reaching $26.41 per share, extending a rally that has seen the stock surge nearly 152% year-to-date. The recent momentum follows a share buyback initiative led by CEO Yat-Gai Au, who repurchased 652,000 shares for $6.19 million, increasing his ownership to 86% of the firm. This move, coupled with broader market speculation, has driven RGC's valuation higher despite ongoing financial challenges.

The company reported net losses of $3.58 million and $4.36 million in the 2025 and 2024 fiscal years, respectively, and has flagged "substantial doubt" about its ability to continue as a going concern. Regencell, which focuses on commercializing Traditional Chinese Medicine for neurocognitive disorders like ADHD and autism, has warned investors of potential operational disruptions and further losses before generating revenue.

While RGC's recent performance has outpaced broader market declines—its shares have risen 218% since October 31, 2025— analysts caution that the stock's volatility reflects speculative trading rather than sustained profitability. Retail investors on platforms like Stocktwits remain divided, with some viewing the stock as a momentum-driven play and others expressing concerns over its long-term viability.

The surge underscores the risks and opportunities inherent in micro-cap biotech investments, where regulatory, financial, and market dynamics can drive rapid price swings. Investors are advised to carefully assess the company's financial disclosures and competitive landscape before making decisions.

Yahoo Finance: Yahoo Finance
Stocktwits: Stocktwits